Neurocrine Biosciences reported robust second-quarter 2026 results anchored by expanded net product sales of INGREZZA and CRENESSITY amid strategic commercial team growth and specialty distribution optimization. The recent acquisition of Soleno Therapeutics broadens Neurocrine's endocrine-focused portfolio with late-stage assets targeting orphan diseases. Outsourced manufacturing and a focused specialty sales force underpin scalable commercialization while advancing a diversified clinical pipeline in neurologic, psychiatric, and endocrinological disorders. Key risks include dependency on a limited number of marketed products and third-party manufacturing continuity. Upcoming milestones involve execution of integration plans and clinical progress within VMAT2 inhibitor candidates.